SCHEMBL25978795

SCHEMBL25978795

CN(C=O)Cc1ccccc1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 5/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
SLC6A3 Q01959 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GAA P10253 2/20 0.38
METAP2 P50579 1/20 0.38
BCAT2 O15382 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
RPS6KB1 P23443 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31213435 0.82 SLC6A2 (0.53) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL168005 0.82 SLC6A2 (0.53) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3884171 0.77 SIRT2 (0.43) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6131533 0.77 TP53 (0.47) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6555382 0.74 MAPT (0.52) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL162322 0.74 MAPT (0.52) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL8930563 0.73 KDM4E (0.47) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL4310308 0.73 MAPT (0.46) MAPTALDH1A1KDM4ETSHRMEN1
SCHEMBL2486332 0.72 TAAR1 (0.50) MAPTALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20581696 0.72 MAPT (0.50) MAPTALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399356-A1 ANTIBODY DRUG CONJUGATES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-14 US disclosed
US-11725024-B2 Antibody drug conjugates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399356-A1 ANTIBODY DRUG CONJUGATES STING1, CGAS, TBK1 MAPT 3123/4885ALDH1A1 4494/4885KDM4E 2002/4885
US-11725024-B2 Antibody drug conjugates STING1, CGAS, TBK1 MAPT 3123/4885ALDH1A1 4494/4885KDM4E 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.